img

Global Cancer CDK Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Cancer CDK Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials.
Cancer CDK Inhibitors report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cancer CDK Inhibitors market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Hospitals and Clinics are the major drivers for the industry.
These inhibitors specifically inhibit CDK4/6 and show limited toxicity to normal cells. There are three FDA-approved CDK4/6 inhibitors and they are Palbociclib produced by Pfizer, Ribociclib produced by Novartis and Abemaciclib produced by Eli Lilly.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cancer CDK Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Pfizer
Novartis
Eli-Lilly
Segment by Type
CDK4/6
CDK2

Segment by Application


Hospitals
Clinics
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cancer CDK Inhibitors market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cancer CDK Inhibitors introduction, etc. Cancer CDK Inhibitors Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cancer CDK Inhibitors market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.

Table of Content

1 Market Overview of Cancer CDK Inhibitors
1.1 Cancer CDK Inhibitors Market Overview
1.1.1 Cancer CDK Inhibitors Product Scope
1.1.2 Cancer CDK Inhibitors Market Status and Outlook
1.2 Global Cancer CDK Inhibitors Market Size Overview by Region 2018 VS 2022 VS 2033
1.3 Global Cancer CDK Inhibitors Market Size by Region (2018-2033)
1.4 Global Cancer CDK Inhibitors Historic Market Size by Region (2018-2023)
1.5 Global Cancer CDK Inhibitors Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Cancer CDK Inhibitors Market Size (2018-2033)
1.6.1 North America Cancer CDK Inhibitors Market Size (2018-2033)
1.6.2 Europe Cancer CDK Inhibitors Market Size (2018-2033)
1.6.3 Asia-Pacific Cancer CDK Inhibitors Market Size (2018-2033)
1.6.4 Latin America Cancer CDK Inhibitors Market Size (2018-2033)
1.6.5 Middle East & Africa Cancer CDK Inhibitors Market Size (2018-2033)
2 Cancer CDK Inhibitors Market by Type
2.1 Introduction
2.1.1 CDK4/6
2.1.2 CDK2
2.2 Global Cancer CDK Inhibitors Market Size by Type: 2018 VS 2022 VS 2033
2.2.1 Global Cancer CDK Inhibitors Historic Market Size by Type (2018-2023)
2.2.2 Global Cancer CDK Inhibitors Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Cancer CDK Inhibitors Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Cancer CDK Inhibitors Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Cancer CDK Inhibitors Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Cancer CDK Inhibitors Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Cancer CDK Inhibitors Revenue Breakdown by Type (2018-2033)
3 Cancer CDK Inhibitors Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.2 Global Cancer CDK Inhibitors Market Size by Application: 2018 VS 2022 VS 2033
3.2.1 Global Cancer CDK Inhibitors Historic Market Size by Application (2018-2023)
3.2.2 Global Cancer CDK Inhibitors Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Cancer CDK Inhibitors Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Cancer CDK Inhibitors Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Cancer CDK Inhibitors Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Cancer CDK Inhibitors Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Cancer CDK Inhibitors Revenue Breakdown by Application (2018-2033)
4 Cancer CDK Inhibitors Competition Analysis by Players
4.1 Global Cancer CDK Inhibitors Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer CDK Inhibitors as of 2022)
4.3 Date of Key Players Enter into Cancer CDK Inhibitors Market
4.4 Global Top Players Cancer CDK Inhibitors Headquarters and Area Served
4.5 Key Players Cancer CDK Inhibitors Product Solution and Service
4.6 Competitive Status
4.6.1 Cancer CDK Inhibitors Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Cancer CDK Inhibitors Products, Services and Solutions
5.1.4 Pfizer Cancer CDK Inhibitors Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Cancer CDK Inhibitors Products, Services and Solutions
5.2.4 Novartis Cancer CDK Inhibitors Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Eli-Lilly
5.3.1 Eli-Lilly Profile
5.3.2 Eli-Lilly Main Business
5.3.3 Eli-Lilly Cancer CDK Inhibitors Products, Services and Solutions
5.3.4 Eli-Lilly Cancer CDK Inhibitors Revenue (US$ Million) & (2018-2023)
5.3.5 Recent Developments
6 North America
6.1 North America Cancer CDK Inhibitors Market Size by Country (2018-2033)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Cancer CDK Inhibitors Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cancer CDK Inhibitors Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cancer CDK Inhibitors Market Dynamics
11.1 Cancer CDK Inhibitors Industry Trends
11.2 Cancer CDK Inhibitors Market Drivers
11.3 Cancer CDK Inhibitors Market Challenges
11.4 Cancer CDK Inhibitors Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Cancer CDK Inhibitors Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2033
Table 2. Global Cancer CDK Inhibitors Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Cancer CDK Inhibitors Market Size Share by Region (2018-2023)
Table 4. Global Cancer CDK Inhibitors Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Cancer CDK Inhibitors Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Cancer CDK Inhibitors Market Size (US$ Million) by Type: 2018 VS 2022 VS 2033
Table 7. Global Cancer CDK Inhibitors Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Cancer CDK Inhibitors Revenue Market Share by Type (2018-2023)
Table 9. Global Cancer CDK Inhibitors Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Cancer CDK Inhibitors Revenue Market Share by Type (2024-2033)
Table 11. North America Cancer CDK Inhibitors Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Cancer CDK Inhibitors Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Cancer CDK Inhibitors Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Cancer CDK Inhibitors Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Cancer CDK Inhibitors Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Cancer CDK Inhibitors Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Cancer CDK Inhibitors Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Cancer CDK Inhibitors Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Cancer CDK Inhibitors Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Cancer CDK Inhibitors Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Cancer CDK Inhibitors Market Size (US$ Million) by Application: 2018 VS 2022 VS 2033
Table 22. Global Cancer CDK Inhibitors Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Cancer CDK Inhibitors Revenue Market Share by Application (2018-2023)
Table 24. Global Cancer CDK Inhibitors Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Cancer CDK Inhibitors Revenue Market Share by Application (2024-2033)
Table 26. North America Cancer CDK Inhibitors Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Cancer CDK Inhibitors Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Cancer CDK Inhibitors Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Cancer CDK Inhibitors Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Cancer CDK Inhibitors Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Cancer CDK Inhibitors Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Cancer CDK Inhibitors Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Cancer CDK Inhibitors Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Cancer CDK Inhibitors Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Cancer CDK Inhibitors Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Cancer CDK Inhibitors Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Cancer CDK Inhibitors Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer CDK Inhibitors as of 2022)
Table 39. Date of Key Players Enter into Cancer CDK Inhibitors Market
Table 40. Global Cancer CDK Inhibitors Key Players Headquarters and Area Served
Table 41. Cancer CDK Inhibitors Product Solution and Service
Table 42. Global Cancer CDK Inhibitors Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Pfizer Basic Information List
Table 45. Pfizer Description and Business Overview
Table 46. Pfizer Cancer CDK Inhibitors Products, Services and Solutions
Table 47. Revenue (US$ Million) in Cancer CDK Inhibitors Business of Pfizer (2018-2023)
Table 48. Pfizer Recent Developments
Table 49. Novartis Basic Information List
Table 50. Novartis Description and Business Overview
Table 51. Novartis Cancer CDK Inhibitors Products, Services and Solutions
Table 52. Revenue (US$ Million) in Cancer CDK Inhibitors Business of Novartis (2018-2023)
Table 53. Novartis Recent Developments
Table 54. Eli-Lilly Basic Information List
Table 55. Eli-Lilly Description and Business Overview
Table 56. Eli-Lilly Cancer CDK Inhibitors Products, Services and Solutions
Table 57. Revenue (US$ Million) in Cancer CDK Inhibitors Business of Eli-Lilly (2018-2023)
Table 58. Eli-Lilly Recent Developments
Table 59. North America Cancer CDK Inhibitors Market Size by Country (2018-2023) & (US$ Million)
Table 60. North America Cancer CDK Inhibitors Market Size by Country (2024-2033) & (US$ Million)
Table 61. Europe Cancer CDK Inhibitors Market Size by Country (2018-2023) & (US$ Million)
Table 62. Europe Cancer CDK Inhibitors Market Size by Country (2024-2033) & (US$ Million)
Table 63. Asia-Pacific Cancer CDK Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 64. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2018-2023) & (US$ Million)
Table 65. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2024-2033) & (US$ Million)
Table 66. Asia-Pacific Cancer CDK Inhibitors Market Share by Region (2018-2023)
Table 67. Asia-Pacific Cancer CDK Inhibitors Market Share by Region (2024-2033)
Table 68. Latin America Cancer CDK Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 69. Latin America Cancer CDK Inhibitors Market Size by Country (2018-2023) & (US$ Million)
Table 70. Latin America Cancer CDK Inhibitors Market Size by Country (2024-2033) & (US$ Million)
Table 71. Middle East & Africa Cancer CDK Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 72. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2018-2023) & (US$ Million)
Table 73. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2024-2033) & (US$ Million)
Table 74. Cancer CDK Inhibitors Market Trends
Table 75. Cancer CDK Inhibitors Market Drivers
Table 76. Cancer CDK Inhibitors Market Challenges
Table 77. Cancer CDK Inhibitors Market Restraints
Table 78. Research Programs/Design for This Report
Table 79. Key Data Information from Secondary Sources
Table 80. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer CDK Inhibitors Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Cancer CDK Inhibitors Market Size (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Cancer CDK Inhibitors Market Share by Regions: 2022 VS 2033
Figure 4. Global Cancer CDK Inhibitors Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Cancer CDK Inhibitors Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Cancer CDK Inhibitors Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Cancer CDK Inhibitors Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Cancer CDK Inhibitors Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Cancer CDK Inhibitors Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of CDK4/6
Figure 11. Global CDK4/6 Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of CDK2
Figure 13. Global CDK2 Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Global Cancer CDK Inhibitors Market Size Share by Type: 2022 & 2033
Figure 15. North America Cancer CDK Inhibitors Revenue Market Share by Type (2018-2033)
Figure 16. Europe Cancer CDK Inhibitors Revenue Market Share by Type (2018-2033)
Figure 17. Asia-Pacific Cancer CDK Inhibitors Revenue Market Share by Type (2018-2033)
Figure 18. Latin America Cancer CDK Inhibitors Revenue Market Share by Type (2018-2033)
Figure 19. Middle East and Africa Cancer CDK Inhibitors Revenue Market Share by Type (2018-2033)
Figure 20. Hospitals Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 21. Clinics Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 22. Global Cancer CDK Inhibitors Market Size Share by Application: 2022 & 2033
Figure 23. North America Cancer CDK Inhibitors Revenue Market Share by Application (2018-2033)
Figure 24. Europe Cancer CDK Inhibitors Revenue Market Share by Application (2018-2033)
Figure 25. Asia-Pacific Cancer CDK Inhibitors Revenue Market Share by Application (2018-2033)
Figure 26. Latin America Cancer CDK Inhibitors Revenue Market Share by Application (2018-2033)
Figure 27. Middle East and Africa Cancer CDK Inhibitors Revenue Market Share by Application (2018-2033)
Figure 28. Cancer CDK Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 29. Global Top 5 and Top 10 Players Cancer CDK Inhibitors Market Share in 2022
Figure 30. North America Cancer CDK Inhibitors Market Share by Country (2018-2033)
Figure 31. U.S. Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 32. Canada Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 33. Germany Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 34. France Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 35. U.K. Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 36. Italy Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 37. Russia Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 38. Nordic Countries Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 39. Asia-Pacific Cancer CDK Inhibitors Market Share by Region (2018-2033)
Figure 40. China Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 41. Japan Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 42. South Korea Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 43. Southeast Asia Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 44. India Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 45. Australia Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 46. Latin America Cancer CDK Inhibitors Market Share by Country (2018-2033)
Figure 47. Mexico Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 48. Brazil Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 49. Middle East & Africa Cancer CDK Inhibitors Market Share by Country (2018-2033)
Figure 50. Turkey Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 51. Saudi Arabia Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 52. UAE Cancer CDK Inhibitors Market Size (2018-2033) & (US$ Million)
Figure 53. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries